CY1123206T1 - Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου - Google Patents

Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου

Info

Publication number
CY1123206T1
CY1123206T1 CY20201100568T CY201100568T CY1123206T1 CY 1123206 T1 CY1123206 T1 CY 1123206T1 CY 20201100568 T CY20201100568 T CY 20201100568T CY 201100568 T CY201100568 T CY 201100568T CY 1123206 T1 CY1123206 T1 CY 1123206T1
Authority
CY
Cyprus
Prior art keywords
myelodysplastic syndrome
telomerase inhibitor
therapeutic management
imetelstat
inhibitor imetelstat
Prior art date
Application number
CY20201100568T
Other languages
English (en)
Inventor
Monic J. STUART
Stephen Kelsey
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of CY1123206T1 publication Critical patent/CY1123206T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Παρέχονται στο παρόν μέθοδοι για τη μείωση του πολλαπλασιασμού νεοπλασματικών προγονικών κυττάρων και την ανακούφιση από συμπτώματα που συνδέονται με οντότητες που έχουν διαγνωστεί με ή πιστεύεται ότι έχουν μυελοδυσπλαστικό σύνδρομο. Επίσης παρέχονται στο παρόν μέθοδοι για τη χρήση αναστολέων τελομεράσης για τη διατήρηση του αριθμού αιμοπεταλίων σε σχετικά φυσιολογικά εύρη στο αίμα των οντοτήτων που έχουν διαγνωστεί με ή υπάρχει υποψία ότι έχουν μυελοδυσπλαστικό σύνδρομο.
CY20201100568T 2012-12-07 2020-06-23 Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου CY1123206T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
EP13861008.4A EP2928477B1 (en) 2012-12-07 2013-11-15 Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
CY1123206T1 true CY1123206T1 (el) 2021-10-29

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101076T CY1122169T1 (el) 2012-12-07 2019-10-14 Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης
CY20201100568T CY1123206T1 (el) 2012-12-07 2020-06-23 Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191101076T CY1122169T1 (el) 2012-12-07 2019-10-14 Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης

Country Status (34)

Country Link
EP (3) EP3456333B8 (el)
JP (5) JP6433911B2 (el)
KR (3) KR102294819B1 (el)
CN (2) CN111617252A (el)
AP (1) AP2015008504A0 (el)
AU (4) AU2013356533B2 (el)
BR (1) BR112015013260A2 (el)
CA (2) CA3188494A1 (el)
CL (2) CL2015001530A1 (el)
CY (2) CY1122169T1 (el)
DK (3) DK3646876T3 (el)
EA (1) EA032973B1 (el)
ES (2) ES2789176T3 (el)
FI (1) FI3646876T3 (el)
HK (2) HK1210940A1 (el)
HR (3) HRP20240624T1 (el)
HU (3) HUE066402T2 (el)
IL (2) IL239266B (el)
LT (3) LT3646876T (el)
MA (2) MA38193B1 (el)
ME (1) ME03538B (el)
MX (3) MX2015007169A (el)
MY (1) MY180634A (el)
NZ (1) NZ708920A (el)
PH (1) PH12015501282A1 (el)
PL (3) PL3456333T3 (el)
PT (3) PT2928477T (el)
RS (2) RS59363B1 (el)
SG (3) SG11201504383TA (el)
SI (3) SI3646876T1 (el)
TN (1) TN2015000249A1 (el)
UA (3) UA128370C2 (el)
WO (1) WO2014088785A1 (el)
ZA (2) ZA201504124B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1778711T1 (sl) 2004-07-02 2017-11-30 Geron Corporation Sinteza zaščitenih 3'-aminonukleozidnih monomerov
HUE042792T2 (hu) * 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére
RS60645B1 (sr) 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TW201919705A (zh) * 2017-07-28 2019-06-01 美商健生生物科技公司 治療骨髓增生不良症候群之方法
IL278345B2 (en) * 2018-04-30 2024-05-01 Kartos Therapeutics Inc Cancer treatment methods
KR20210038895A (ko) * 2018-07-31 2021-04-08 제론 코포레이션 텔로머라제 억제제에 의한 치료로부터 이익일 것 같은 환자를 확인하는 방법
JP2023500326A (ja) * 2019-11-04 2023-01-05 ジェロン・コーポレーション 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
SI1778711T1 (sl) 2004-07-02 2017-11-30 Geron Corporation Sinteza zaščitenih 3'-aminonukleozidnih monomerov
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PL2101789T3 (pl) * 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
HRP20191784T1 (hr) 2019-12-27
AU2024203138A1 (en) 2024-07-25
CL2017002156A1 (es) 2018-05-04
CA2892907C (en) 2023-03-21
CN104936602A (zh) 2015-09-23
MA45504A1 (fr) 2020-05-29
ZA202108991B (en) 2023-05-31
IL239266A0 (en) 2015-07-30
KR20210107906A (ko) 2021-09-01
EP3456333B8 (en) 2020-05-13
AU2020267142C1 (en) 2024-08-08
PL3456333T3 (pl) 2020-09-21
CL2015001530A1 (es) 2016-03-28
HK1210940A1 (en) 2016-05-13
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
ES2744790T3 (es) 2020-02-26
EP2928477A4 (en) 2016-09-21
SI2928477T1 (sl) 2019-11-29
WO2014088785A8 (en) 2015-07-16
IL280144A (en) 2021-03-01
EP3646876B1 (en) 2024-02-14
JP6998191B2 (ja) 2022-02-04
JP2018035196A (ja) 2018-03-08
TN2015000249A1 (en) 2016-10-03
JP2022179684A (ja) 2022-12-02
MX2015007169A (es) 2016-03-31
ME03538B (me) 2020-07-20
NZ708920A (en) 2020-08-28
PL3646876T3 (pl) 2024-07-22
JP6433911B2 (ja) 2018-12-05
EP3456333B1 (en) 2020-04-01
RS60401B1 (sr) 2020-07-31
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
KR20230028590A (ko) 2023-02-28
UA128370C2 (uk) 2024-06-26
SG10201802926XA (en) 2018-05-30
AU2020267142B2 (en) 2024-05-16
CY1122169T1 (el) 2020-11-25
KR102294819B1 (ko) 2021-09-01
JP2020041001A (ja) 2020-03-19
KR20150091130A (ko) 2015-08-07
IL239266B (en) 2019-11-28
AP2015008504A0 (en) 2015-06-30
PH12015501282B1 (en) 2015-08-24
EA032973B1 (ru) 2019-08-30
SG10202103341SA (en) 2021-05-28
LT3456333T (lt) 2020-06-25
MY180634A (en) 2020-12-03
KR102662590B1 (ko) 2024-05-03
MX2020003276A (es) 2020-07-20
RS59363B1 (sr) 2019-11-29
ES2789176T3 (es) 2020-10-26
MX2022015437A (es) 2023-01-11
EP2928477A1 (en) 2015-10-14
PL2928477T3 (pl) 2020-03-31
CN104936602B (zh) 2020-07-17
AU2013356533A1 (en) 2014-06-12
ZA201504124B (en) 2017-05-31
UA126015C2 (uk) 2022-08-03
WO2014088785A1 (en) 2014-06-12
MA38193B1 (fr) 2018-12-31
HUE066402T2 (hu) 2024-07-28
HRP20240624T1 (hr) 2024-08-02
EP3456333A1 (en) 2019-03-20
HK1212226A1 (en) 2016-06-10
NZ748134A (en) 2020-10-30
CN111617252A (zh) 2020-09-04
JP2016504307A (ja) 2016-02-12
JP7288098B2 (ja) 2023-06-06
SI3646876T1 (sl) 2024-07-31
DK3646876T3 (da) 2024-05-06
MA38193A1 (fr) 2017-12-29
FI3646876T3 (fi) 2024-05-14
LT3646876T (lt) 2024-05-10
HUE049858T2 (hu) 2020-11-30
SI3456333T1 (sl) 2020-10-30
PT3646876T (pt) 2024-05-15
PT3456333T (pt) 2020-06-01
CA2892907A1 (en) 2014-06-12
CA3188494A1 (en) 2014-06-12
AU2020267142A1 (en) 2020-12-03
PH12015501282A1 (en) 2015-08-24
MA45504B1 (fr) 2021-10-29
DK3456333T3 (da) 2020-05-18
EP2928477B1 (en) 2019-07-24
SG11201504383TA (en) 2015-07-30
LT2928477T (lt) 2019-10-10
AU2013356533B2 (en) 2018-09-27
AU2018282364A1 (en) 2019-05-23
EA201590878A1 (ru) 2016-04-29
BR112015013260A2 (pt) 2018-02-06
UA117116C2 (uk) 2018-06-25
PT2928477T (pt) 2019-10-25
JP2022050537A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
CY1123206T1 (el) Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου
CY1123647T1 (el) Διαμορφωση της ανοσιας ογκων
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
BR112013023265A2 (pt) artigos absorventes descartáveis com uma camada superior gofrada
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2015002807A1 (es) Terapia de combinación
DK2970132T3 (da) Argininmethyltransferaseinhibitorer og anvendelser deraf
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
AU2013323736A8 (en) Multiple kinase pathway inhibitors
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
BR112015029858A2 (pt) toalha sanitária
BR112013027728A2 (pt) distribuidor com braçadeira de fixação
DK3284463T3 (da) Nitroxyldonorer med forbedret terapeutisk indeks
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
BR112015014609A2 (pt) artigo absorvente que compreende pelo menos duas almofadas absorventes individuais empilhadas
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
UY34829A (es) Nueva dosificación y formulación
DK2945996T3 (da) Hybridpolymer med højt klyngeindhold
CY1117170T1 (el) Συνθεση ολιγοσακχαριτων για προληψη ή μειωση του κινδυνου μεταβολικου συνδρομου
BR112014027230A2 (pt) lanterna com punho de fixação integrado
UY4240Q (es) Silla con respaldo en forma oval